EP3842457A1 — Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
Assigned to Novartis AG · Expires 2021-06-30 · 5y expired
What this patent protects
The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.
USPTO Abstract
The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.
Drugs covered by this patent
- glycopyrrolate (Glycopyrrolate) · Yonsei University
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.